Zai Lab Ltd — fact timeline

Zai Lab Ltd shareholders approved Approve general mandate to repurchase shares up to 10% at the 2026-06-17 meeting.

“Proposal 14 : An ordinary resolution to approve a general mandate to repurchase ordinary shares and/or ADSs of up to 10% of the total number of issued ordinary shares of the Company (excluding treasury shares) as of the date of the Annual Meeting until the 2027 annual general meeting of shareholders. For Against Abstentions Broker Non-Votes 547,258,396 25,670 2,997,801 - Accordingly, Proposal 14 was carried as an ordinary resolution.”

Zai Lab Ltd shareholders approved Approve general mandate to allot and issue shares up to 10% at the 2026-06-17 meeting.

“Proposal 13 : An ordinary resolution to approve a general mandate to the Board of Directors to allot and issue ordinary shares and/or ADSs and/or resell treasury shares of up to 10% of the total number of issued ordinary shares of the Company (excluding treasury shares) as of the date of the Annual Meeting until the 2027 annual general meeting of shareholders. For Against Abstentions Broker Non-Votes 546,131,045 1,077,021 3,073,801 - Accordingly, Proposal 13 was carried as an ordinary resolution.”

Zai Lab Ltd shareholders approved Advisory vote on compensation of named executive officers at the 2026-06-17 meeting.

“Proposal 12 : An ordinary resolution to approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the Proxy Statement. For Against Abstentions Broker Non-Votes 392,663,823 154,589,463 3,028,581 - Accordingly, the Company’s shareholders voted for an advisory vote on the compensation of the named executive officers, as disclosed in the Proxy Statement. Proposal 12 was carried as an ordinary resolution.”

Zai Lab Ltd shareholders approved Authorize the board to fix auditor compensation for 2026 at the 2026-06-17 meeting.

“Proposal 11 : An ordinary resolution to authorize the board of directors of the Company (the “Board of Directors”) to fix auditor compensation for 2026. For Against Abstentions Broker Non-Votes 546,562,816 714,770 3,004,281 - Accordingly, Proposal 11 was carried as an ordinary resolution.”

Zai Lab Ltd shareholders approved Approve the appointment of KPMG LLP and KPMG as auditors at the 2026-06-17 meeting.

“Proposal 10 : An ordinary resolution to approve the appointment of KPMG LLP and KPMG as the Company’s independent registered public accounting firms and auditors to audit our consolidated financial statements to be filed with the SEC and the Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”) for the year ending December 31, 2026, respectively. For Against Abstentions Broker Non-Votes 547,252,626 29,640 2,999,601 - Accordingly, Proposal 10 was carried as an ordinary resolution.”

Zai Lab Ltd shareholders approved Re-election of nine directors to the Board at the 2026-06-17 meeting.

“Proposals 1 to 11 and 13 to 14 in the notice of the Annual Meeting were approved at the Annual Meeting.”

Josh Smiley departed as President and Chief Operating Officer at Zai Lab Ltd.

“On May 18, 2026, the Board of Directors of Zai Lab Limited (the “Company”) determined that Mr. Josh Smiley will cease serving as President and Chief Operating Officer of the Company, effective as of May 18, 2026, and his last day of employment with the Company will be May 22, 2026.”

Zai Lab Ltd reported the first quarter of 2026 results: revenue $99.6 million, net income Net loss was $51.0 million, EPS loss per ADS of $0.46.

“forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate Updates – Total revenues of $99.6 million for the first quarter of 2026, reflecting anticipated first-quarter dynamics, including certain competitive impacts for ZEJULA and pricing adjustment related to NRDL renewal for”

Harald Reinhart retired as President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases at Zai Lab Ltd.

“On June 11, 2024 , Zai Lab Limited (the “Company”) announced that Dr. Harald Reinhart, President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases, has informed the Company that he has decided to retire, effective June 30, 2024.”

Zai Lab Ltd reported the first quarter of 2024 results: revenue $87.1 million, net income $53.5 million, EPS loss per ordinary share attributable to common stockholders of $0.05 (or loss per American Deposit Share (ADS) of $0.55).

“by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Zai Lab Announces First Quarter 2024 Financial Results and Recent Corporate Updates – Net product revenue of $87.1 million for the first quarter of 2024, representing 39% y-o-y growth; 43% y-o-y growth at constant exchange rate (CER) – VYVGART ® (efgartigimod alfa injection) sales of $13.2 million”

Zai Lab Ltd reported the year ended December 31, 2023 results: revenue $266.7 million, net income $334.6 million, EPS loss per ordinary share attributable to common stockholders of $0.35 (or loss per American Deposit Share ("ADS") of $3.4.

“by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates – Total product revenue of $266.7 million for Full-Year 2023, representing 25% y-o-y growth; 31% y-o-y growth at constant exchange rate (CER) – VYVGART ® (efgartigimod alfa injection) was launched in September 2023 in”

Zai Lab Ltd incurred credit facility of up to RMB230.3 million (approximately $32.4 million), of which the Company is authorized to utilize up to RMB160 million with Bank of Ningbo Co., Ltd. Suzhou Sub-branch.

“Zai Lab (Suzhou) Co., Ltd. (“Zai Lab Suzhou”), entered into a maximum credit contract (the “Maximum Credit Contract”) with Bank of Ningbo Co., Ltd. Suzhou Sub-branch (“Ningbo Bank”). The Ningbo Bank Agreements permit Zai Lab Suzhou to utilize, including through discounting or working capital loan agreements and subject to the terms and conditions in related master agreements, up to RMB230.3 million (approximately $32.4 million), of which the Company is authorized to utilize up to RMB160 million (approximately $22.5 million).”

Zai Lab Ltd incurred guarantee of up to RMB300 million (approximately $42 million) with Shanghai Pudong Development Bank Co., Ltd. Zhangjiang Hi-Tech Park Sub-branch maturing three-year period.

“the Company entered into a maximum-amount guarantee contract (the “Guarantee”) with the Shanghai Pudong Development Bank Co., Ltd. Zhangjiang Hi-Tech Park Sub-branch (the “SPD Bank”) pursuant to which the Company will guarantee working capital loans of up to RMB300 million (approximately $42 million) from SPD Bank to Zai Lab Shanghai over a three-year period.”

Zai Lab Ltd incurred term loan of RMB340 million (approximately $47.8 million) with Bank of China Pudong Development Zone Branch at latest one-year loan prime rate published by the National Interbank Funding Cent maturing one year.

“Zai Lab Shanghai subsequently entered into a working capital loan contract (the “Working Capital Loan Agreement”) with the BOC Pudong Branch on February 7, 2024 for a loan of RMB340 million (approximately $47.8 million).”

Zai Lab Ltd incurred credit facility of $100 million with Bank of China (Hong Kong) Limited maturing one year.

“the Company entered into an uncommitted facility letter (the “Facility Letter”) with the Bank of China (Hong Kong) Limited (the “BOC HK”) pursuant to which the BOC HK will provide standby letters of credit for loans of up to $100 million for a term of one year.”

Zai Lab Ltd entered into Maximum Credit Contract with Bank of Ningbo Co., Ltd. Suzhou Sub-branch valued at up to RMB230.3 million (approximately $32.4 million) (effective 2024-02-06).

“On February 6, 2024, our wholly-owned subsidiary, Zai Lab (Suzhou) Co., Ltd. (“Zai Lab Suzhou”), entered into a maximum credit contract (the “Maximum Credit Contract”) with Bank of Ningbo Co., Ltd. Suzhou Sub-branch (“Ningbo Bank”).”

Zai Lab Ltd entered into Guarantee with Shanghai Pudong Development Bank Co., Ltd. Zhangjiang Hi-Tech Park Sub-branch valued at up to RMB300 million (approximately $42 million) (effective 2024-02-06).

“On February 6, 2024, the Company entered into a maximum-amount guarantee contract (the “Guarantee”) with the Shanghai Pudong Development Bank Co., Ltd. Zhangjiang Hi-Tech Park Sub-branch (the “SPD Bank”) pursuant to which the Company will guarantee working capital loans of up to RMB300 million (approximately $42 million) from SPD Bank to Zai Lab Shanghai over a three-year period.”

Zai Lab Ltd entered into Working Capital Loan Agreement with Bank of China Pudong Development Zone Branch valued at RMB340 million (approximately $47.8 million) (effective 2024-02-07).

“Zai Lab Shanghai subsequently entered into a working capital loan contract (the “Working Capital Loan Agreement”) with the BOC Pudong Branch on February 7, 2024 for a loan of RMB340 million (approximately $47.8 million).”

Zai Lab Ltd entered into Facility Letter with Bank of China (Hong Kong) Limited valued at $100 million (effective 2024-02-05).

“On February 5, 2024, the Company entered into an uncommitted facility letter (the “Facility Letter”) with the Bank of China (Hong Kong) Limited (the “BOC HK”) pursuant to which the BOC HK will provide standby letters of credit for loans of up to $100 million for a term of one year.”

Zai Lab Ltd reported third quarter 2023 results: revenue $69.2 million, net income $69.2 million, EPS $0.07.

“Third Quarter 2023 Financial Results • Product revenues were $69.2 million for the third quarter of 2023, compared to $57.0 million for the same period in 2022, representing 22% y-o-y growth and 27% y-o-y growth at CER. This increase was primarily driven by increased sales volumes, the launch of VYVGART, and decreased negative effects from the COVID-19 pandemic . Our revenue growth was slowed by the effects on hospital and physician practices from the recent industry-wide anti-corruption enforcement efforts in China. Product revenues in the third quarter of 2023, compared to the same period in 2022, included: – $41.6 million for ZEJULA, which increased from $39.2 million, as ZEJULA, which is in its third year on the NRDL, continued to be the leading PARP inhibitor in hospital sales for ovarian cancer in China; – $11.6 million for Optune, which increased from $10.7 million, supported by increased patient access to this product in the private-pay market; – $5.7 million for QINLOCK, which”

Zai Lab Ltd reported the second quarter of 2023 results: revenue $68.9 million.

“Total product revenue of $68.9 million for the second quarter of 2023”

William Cho departed as Chief Financial Officer at Zai Lab Ltd.

“Also on July 6, the Company announced that Dr. Chen will be succeeding William Cho, who is stepping down from his role as Chief Financial Officer, effective July 7, 2023.”

Yajing Chen was appointed as Chief Financial Officer at Zai Lab Ltd.

“On July 6, 2023, Zai Lab Limited (the “Company”) announced that it has appointed Dr. Yajing Chen as its Chief Financial Officer, effective July 7, 2023.”

Zai Lab Ltd shareholders approved Approve a general mandate to allot and issue ordinary shares and/or ADSs up to 20% of issued shares at the 2023-06-20 meeting.

“Proposal 14 : (14) AS AN ORDINARY RESOLUTION: to approve a general mandate to the Board of Directors to allot and issue ordinary shares and/or ADSs of up to 20% of the total number of issued ordinary shares of the Company as of the date of passing of such ordinary resolution up to the 2024 annual general meeting of shareholders. For Against Abstentions Broker Non-Votes 445,577,099 415,625,301 10,776,490 - Accordingly, Proposal 14 was carried”

Zai Lab Ltd shareholders approved Advisory vote on compensation of named executive officers at the 2023-06-20 meeting.

“Proposal 13 : (13) AS AN ORDINARY RESOLUTION: to approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the Proxy Statement. For Against Abstentions Broker Non-Votes 528,433,772 332,768,748 10,776,370 - Accordingly, the Company’s shareholders voted for an advisory vote on the compensation of the named executive officers, as disclosed in the Proxy Statement. Proposal 13 was carried as an ordinary resolution.”

Zai Lab Ltd shareholders approved Authorize the board of directors to fix auditor compensation for 2023 at the 2023-06-20 meeting.

“Proposal 12 : (12) AS AN ORDINARY RESOLUTION: to authorize the board of directors of the Company (the Board of Directors) to fix auditor compensation for 2023. For Against Abstentions Broker Non-Votes 871,888,360 66,680 23,850 - Accordingly, Proposal 12 was carried as an ordinary resolution.”

Zai Lab Ltd shareholders approved Approve the appointment of KPMG LLP and KPMG as the Company’s independent registered public accounting firms and auditors at the 2023-06-20 meeting.

“Proposal 11 : (11) AS AN ORDINARY RESOLUTION: to approve the appointment of KPMG LLP and KPMG as the Company’s independent registered public accounting firms and auditors to audit our consolidated financial statements to be filed with the SEC and the Stock Exchange of Hong Kong Limited (the Hong Kong Stock Exchange) for the year ending December 31, 2023, respectively. For Against Abstentions Broker Non-Votes 871,945,920 10,640 22,330 - Accordingly, Proposal 11 was carried as an ordinary resolution.”

Zai Lab Ltd shareholders approved Re-election of directors at the 2023-06-20 meeting.

“Proposal 1 : (1) AS AN ORDINARY RESOLUTION: to re-elect Samantha (Ying) Du to serve as a director until the 2024 annual general meeting of shareholders and until her successor is duly elected and qualified, subject to her earlier resignation or removal. For Against Abstentions Broker Non-Votes 864,416,850 5,947,360 1,614,680 - Accordingly, Proposal 1 was carried as an ordinary resolution.”

Zai Lab Ltd reported the first quarter of 2023 results: revenue $62.8 million.

“Total product revenue of $62.8 million for the first quarter of 2023”

Zai Lab Ltd reported the year ended December 31, 2022 results: revenue $215.0 million.

“ai Lab Announces Full-Year 2022 Financial Results and Recent Corporate Updates – Total revenue of $215.0 million for 2022, representing a 49.0% increase y-o-y; ZEJULA ® achieved 55.2% y-o-y growth – Strong balance sheet with a cash position of $1.0 billion as of December 31, 2022 – Company to host conference call and webcast on March 2, 2023, at 8:00 a.m.”

Michel Vounatsos was appointed as independent director at Zai Lab Ltd.

“On January 7, 2023, the Board of Directors (the “Board”) of Zai Lab Limited (the “Company”) appointed Michel Vounatsos as an independent director, effective immediately.”

Zai Lab Ltd reported the three months ended September 30, 2022 results: revenue $57.5 million.

“expressly set forth by specific reference in such filing. --- EX-99.1 (EX-99.1) --- Zai Lab Announces Third Quarter 2022 Financial Results and Corporate Updates – Revenue of $57.5 million for the third quarter of 2022, representing a 33% increase y-o-y and a 19% increase q-o-q; continued revenue growth led by ZEJULA – Regional strategic collaboration for TIVDAK ®”

Dr. Alan Sandler departed as other_named_officer at Zai Lab Ltd.

“Dr. Alan Sandler who provided notice that he is resigning from the Company, effective October 28, 2022, to pursue another professional opportunity.”

Joshua Smiley was appointed as Chief Operating Officer at Zai Lab Ltd.

“Zai Lab Limited (the “Company”) appointed Joshua Smiley as the Company’s Chief Operating Officer, effective on August 1, 2022”

Tao Fu resigned as Chief Strategy Officer at Zai Lab Ltd.

“On March 28, 2022, Tao Fu, Chief Strategy Officer of Zai Lab Limited (the “Company”), provided notice to the Company of his resignation from the Company, effective as of the close of business on April 8, 2022.”

Joshua Smiley was appointed as Chief Operating Officer at Zai Lab Ltd.

“On March 15, 2022, Zai Lab Limited (the “Company”) announced the appointment of Joshua Smiley as the Company’s Chief Operating Officer.”

Harald Reinhart changed role as President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases at Zai Lab Ltd.

“On December 22, 2021, Zai Lab Limited (the “Company”) announced the promotion of Harald Reinhart, M.D., from his current role as Chief Medical Officer to President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases.”

Richard Gaynor was appointed as Independent Director at Zai Lab Ltd.

“On November 19, 2021 (U.S. Eastern Time), the Board of Directors (the “Board”) of Zai Lab Limited (the “Company”) appointed Richard Gaynor as an independent director, effective immediately.”

Scott W. Morrison was appointed as independent director at Zai Lab Ltd.

“On October 13, 2021 (U.S. Eastern Time), the Board of Directors (the “Board”) of Zai Lab Limited (the “Company”) appointed Scott W. Morrison as an independent director, effective immediately.”